This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): BMS-982470, recombinant interleukin 21 (rIL-21), NN028
Description: IL-21 is a novel member of the 4 helical bundle cytokine family, a protein family well-validated as having therapeutic potential. IL-21 has potent biological activity in regulating key classes of immune cells, including cytotoxic T cells and natural killer cells.
Deal Structure: IL-21 was originally developed by ZymoGenetics.
Novo Nordisk and ZymoGenetics
In June 2001, Novo Nordisk gave notice of its intent to exercise an option to license rights to IL-21 outside of North America pursuantto ZymoGenetics' option agreement with Novo Nordisk.
In January 2009, ZymoGenetics announced the acquisition of ex-North American rights to Interleukin 21 (IL-21) from Novo Nordisk, resulting in ZymoGenetics owning worldwide rights to IL-21. Under the terms of the arrangement, Novo Nordisk agreed to license rest of world (ex-North American) development and commercialization rights for IL-21 to ZymoGenetics in exchange for potential regulatory approval milestones and royalties related to the ex-North American territory. In addition, upon licensing worldwide rights for IL-21 to a third party, Novo Nordisk would receive a portion of related licensing fees if a certain threshold level were exceeded.
Bristol-Myers Squibb and ZymoGenetics
In September...See full deal structure in Biomedtracker
Partners: Novo Nordisk A/S
Additional information available to subscribers only: